Effect of ribavirin, in combination with interferon in patients with hepatitis C, on the bleeding risk associated with selective serotonin reuptake inhibitors.
Honda
Takashi
T
Katano
Yoshiaki
Y
Toyoda
Hidenori
H
Hayashi
Kazuhiko
K
Ishigami
Masatoshi
M
Nakano
Isao
I
Goto
Hidemi
H
Yamamoto
Koji
K
Takamatsu
Junki
J
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005167:Factor VII / Q000037:antagonists & inhibitors / Q000378:metabolism; D006467:Hemophilia A / Q000150:complications* / Q000378:metabolism; D006470:Hemorrhage / Q000139:chemically induced*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D001523:Mental Disorders / Q000150:complications* / Q000188:drug therapy*; D012254:Ribavirin / Q000627:therapeutic use*; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D000998:Antiviral Agents; D005167:Factor VII; D016898:Interferon-alpha; D012254:Ribavirin; D017367:Selective Serotonin Reuptake Inhibitors